10 important updates for International HPV Awareness Day
Click Here to Manage Email Alerts
Today is International HPV Awareness Day.
The observance — first held in 2018 — is part of International Papilloma Society’s effort to increase understanding of HPV and the importance of managing risk for HPV-related cancers.
In conjunction with this effort, Healio provides the following important updates about the role HPV plays in cancer development and measures undertaken to increase vaccination uptake.
• Health care providers should begin offering routine HPV vaccination to children as young as age 9 years in order to increase rates of on-time administration, according to an updated American Cancer Society guideline. Read more.
• In this installment of Point/Counter, two clinicians who specialize in obstetrics and gynecology debate whether HPV self-testing should be usual care in the United States. Read more.
• Oral HPV was prevalent in nearly 23% of newborns and persisted in approximately 15% of children for more than a year after birth. Read more.
• Incidence of anal cancer — associated with HPV and HIV infections — has increased significantly among women and those aged older than 50 years. Read more.
• Approximately 70% of U.S. adolescents are not up to date on routine vaccinations for HPV, meningococcal disease and tetanus, diphtheria and pertussis by age 17 years. Read more.
• Early post-therapy clearance of HPV appeared associated with improved survival among women with cervical cancer. Read more.
• Quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer among Swedish girls and women aged 10 to 30 years. Read more.
• An educational comic book about HPV improved college students’ attitudes about completing the vaccination process and their intention to do so within 1 year. Read more.
• De-escalated intensity-modulated radiotherapy plus concurrent cisplatin satisfied criteria for further study among patients with HPV-related oropharyngeal squamous cell carcinoma, according to phase 2 study results. Read more.
• The FDA expanded the indication of HPV 9-valent vaccine, recombinant (Gardasil 9, Merck) to include prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts